Welcome to the Centre for Bioengineering and Biotechnology at the University of Waterloo
The Centre for Bioengineering and Biotechnology is a catalyst for advancing bioengineering and biotechnology research and innovation through industry collaborations and partnerships.
More than 150 faculty members, from every faculty on campus, are actively engaged with the centre, working in collaboration to provide a resource of varying expertise.
Our mandate is to build healthy, active partnerships between centre researchers and corporate members through collaborative projects, mutual interest building, and networking events.
To learn more about partnerships, please email us.
- June 5, 2020
The Centre for Bioengineering and Biotechnology along and the University of Waterloo Office of Research are pleased to announce that Professor Karim S. Karim has accepted the role of Executive Director for a term of five years, ending March 31, 2025.
- Apr. 16, 2020
Researchers at the University of Waterloo are developing a DNA-based vaccine that can be delivered through a nasal spray.
The vaccine will work by using bacteriophage, a process that will allow the vaccine to replicate within bacteria already in the body and is being designed to target tissues in the nasal cavity and lower respiratory tract.
- Mar. 28, 2020
The current COVID-19 pandemic has been putting a strain on healthcare workers around the world. We often forget all the challenges that frontline healthcare professionals have to face, including the use of personal protective equipment. This paper from 2016 describes the evaluation during the ebola crisis, which has excellent recommendations for healthcare workers and managers around the world when dealing with COVID-19.
- Sep. 23, 2020
COVID-19 has brought disease and mortality at levels not seen from a respiratory virus for over 100 years. Immune responses to this virus, which can infect several different tissues, are poorly understood, including the role of antibodies in resolving the infection. In March 2020, we reoriented our lab to develop Enzyme-Linked ImmunoSorbent Assays (ELISA) for human antibody isotypes IgM, IgG and IgA produced in response to the SARS-CoV-2 spike protein. To date we have analyzed samples from 114 patients, including both PCR positive and PCR negative individuals.
- Oct. 7, 2020
Rohan Shanbhag will be discussing how Achu Health has developed an application based on a machine learning algorithm that uses data collected from a smartwatch to predict illness in individuals using the application.